Trial Profile
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma; Renal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms IL2HD
- 25 Feb 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.
- 20 Apr 2020 Planned End Date changed from 1 Jun 2019 to 1 Jun 2022.
- 20 Apr 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.